Ongoing Clinical Trials

HCC is an aggressive, largely chemo-resistant cancer with a poor prognosis, currently there is no effective systemic chemotherapy for HCC. Vascular endothelial growth factor (VEGF), a potent stimulator of angiogenesis, is overexpressed in HCC and thought to contribute to tumor development. Oxaliplatin in combination with other chemotherapies or biologic agents have been shown to be an effective and safe treatment in advanced HCC patients. Sorafenib, an oral multi-kinase inhibitor, blocks tumor cell proliferation by targeting multiple growth factor pathways and also exerts an anti-angiogenic effect via inhibition of VEGF.

This study aims to evaluate combination of Sorafenib and a combining chemotherapy (Capecitabine and Oxaliplatin) cytotoxic drug to achieve tumor shrinkage in locally advanced or metastatic HCC patients.

1. Diagnosed hepatocellular carcinoma (HCC)
2. No prior systemic therapy
3. Have preserved liver function

1. Patients with ascites uncontrolled by medication
2. Patients with main portal vein tumor thrombosis or have extrahepatic disease
3. Patients unable to swallow oral medications